You are here: Industry Insights > Valneva

News List

Valneva, Dynavax Enter COVID-19 Vax Supply Pact contractpharma
September 16, 2020
Dynavax will supply CpG 1018 to produce up to 100 million doses of VLA2001 vaccine in 2021.
Valneva Wins DoD Contract for IXIARO contractpharma
September 14, 2020
Will supply Japanese encephalitis vaccine IXIARO under a new contract lasting up to three years.
Valneva Appoints Chief Medical Officer contractpharma
August 10, 2020
Valneva SE, a specialty vaccine company focused on prevention of diseases with major unmet needs, has appointed Juan Carlos Jaramillo, MD as chief medical officer and member of the Management Board starting October 1, 2020.
UK and Valneva to invest in coronavirus vaccine manufacturing pharmaceutical-technology
August 06, 2020
The UK Government and biotech company Valneva are set to make a joint investment in a manufacturing facility in Livingston, West Lothian as part of an agreement for early access to 60 million doses of the company’s Covid-19 vaccine candidate.
UK Government secures early access to 90 million doses of COVID-19 vaccines europeanpharmaceuticalreview
July 21, 2020
The government has entered partnerships with Pfizer and Valneva to secure doses of several promising COVID-19 vaccines and secured COVID-19 neutralising antibody treatments from AstraZeneca.
Valneva to Provide SARS-CoV-2 Vax Candidate to UK Govt contractpharma
July 21, 2020
Valneva's VLA2001, an inactivated whole virus vaccine candidate against coronavirus is expected to enter clinical studies by the end of 2020.
Valneva, Bavarian Nordic Announce Marketing and Distribution Partnership americanpharmaceuticalreview
June 30, 2020
Valneva and Bavarian Nordic have signed a binding term sheet to establish a partnership for the marketing and distribution of their commercial products.
Valneva Earns $130M Pfizer Milestone in Lyme Vax Pact contractpharma
June 10, 2020
Working to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase II clinical studies.
Valneva and Pfizer collaborate for Lyme disease vaccine expresspharma
May 04, 2020
VLA15 is the only active Lyme disease vaccine programme in clinical development today, and covers six serotypes that are prevalent in North America and Europe.
Valneva secures CEPI grant to develop Chikungunya vaccine pharmaceutical-technology
July 26, 2019
French biotech firm Valneva has received a grant of up to $23.4m from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a single-dose, live-attenuated Chikungunya vaccine.

Previous page 1 2 3 4 5 Next page